| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
|
Medicine details |
|
| Medicine name | dapagliflozin/metformin (Xigduo®) |
| Formulation | 5 mg/850 mg, 5 mg/1,000 mg film-coated tablet |
| Reference number | 1085 |
| Indication | In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone; in combination with other glucose lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products; and in patients already being treated with the combination of dapagliflozin and metformin as separate tablets |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/12/2013 |
| NICE guidance | TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |